Targeted Delivery of Rosiglitazone for Traumatic Brain Injury Using 2DG-Functionalized Dendrimer
Friday, July 18, 2025
9:24 AM - 9:35 AM EDT
Location: 122 B
Introduction: Rosiglitazone, a potent PPARγ agonist, has demonstrated significant neuroprotective effects in animal models of CNS disorders. However, its clinical application is hindered due to poor blood brain barrier (BBB) penetration, low water solubility, and systemic side effects, including cardiovascular risks. These limitations restrict its therapeutic potential, highlighting the need for advanced delivery systems.
Learning Objectives:
At the completion of this activity, participants will know
Describe the need for brain targeted drug delivery for rosiglitazone.
Demonstrate the development of an efficient brain targeted drug delivery system.
Demonstrate 2DG-D's role in targeted brain drug delivery, improving pharmacokinetics and efficacy
Aqib Iqbal Dar – Post Doc, Chemistry, Washington State University; Zhi Zhang – Professor, Natural Sciences, University of Michigan -Dearborn; Anjali Sharma – Professor, Chemistry, Washington State University
